Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 8, 2012, Pages 1341-1347

  Jin, Young Joo ^a   Kim, Kang Mo ^a   Hwang, Shin ^a   Lee, Sung Gyu ^a   Ha, Tae Yong ^a   Song, Gi Won ^a   Jung, Dong Hwan ^a   Kim, Ki Hun ^a   Yu, Eunsil ^a   Shim, Ju Hyun ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yungsang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Exercise and diet modification; Liver donor; Non alcoholic fatty liver disease; Steatosis; Total cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIET; EXERCISE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEATOSIS; WEIGHT REDUCTION;

EID: 84864310125     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07165.x     Document Type: Article

References (33)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003; 98: 960-7.
2. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
3. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009; 50: 204-10.
4. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 163-72.
5. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J. Gastroenterol. Hepatol. 2004; 19: 368-74.
6. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21years. Hepatology 1990; 11: 74-80.
7. Kim HJ, Lee KE, Kim DJ etal. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 2169-75.
8. Omagari K, Kadokawa Y, Masuda J etal. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1098-105.
9. Chen CH, Huang MH, Yang JC etal. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J. Clin. Gastroenterol. 2006; 40: 745-52.
10. Lee JY, Kim KM, Lee SG etal. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol. 2007; 47: 239-44.
11. Hwang S, Lee SG, Jang SJ etal. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl. 2004; 10: 721-5.
12. Nakamuta M, Morizono S, Soejima Y etal. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005; 80: 608-12.
13. D'Alessandro AM, Kalayoglu M, Sollinger HW etal. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant. Proc. 1991; 23: 1536-7.
14. Marsman WA, Wiesner RH, Rodriguez L etal. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-51.
15. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829-38.
16. Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin. Liver Dis. 2009; 13: 667-88.
17. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
18. Ueno T, Sugawara H, Sujaku K etal. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997; 27: 103-7.
19. Anderson JW, Hamilton CC, Brinkman-Kaplan V. Benefits and risks of an intensive very-low-calorie diet program for severe obesity. Am. J. Gastroenterol. 1992; 87: 6-15.
20. Sweeney ME, Hill JO, Heller PA, Baney R, Digirolamo M. Severe versus moderate energy restriction with and without exercise in the treatment of obesity-efficiency of weight-loss. Am. J. Clin. Nutr. 1993; 57: 127-34.
21. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-54.
22. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
23. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
24. Marcos A. Right lobe living donor liver transplantation: a review. Liver Transpl. 2000; 6: 3-20.
25. Kukkonen K, Rauramaa R, Siitonen O, Hanninen O. Physical training of obese middle-aged persons. Ann. Clin. Res. 1982; 14 (Suppl. 34): 80-5.
26. Yamamoto R, Inoue S, Saito M, Okamoto M, Okamura A, Takamura Y. Very-low-calorie-diet therapy in severe obesity. Am. J. Clin. Nutr. 1992; 56: S299-302.
27. Oscai LB, Holloszy JO. Effects of weight changes produced by exercise, food restriction, or overeating on body composition. J. Clin. Invest. 1969; 48: 2124-8.
28. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Washington, DC: US Department of Health and Human Services, 1998.
29. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
30. Promrat K, Kleiner DE, Niemeier HM etal. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
31. Nobili V, Manco M, Devito R etal. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-28.
32. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
33. Ascaso J, Gonzalez Santos P, Hernandez Mijares A etal. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Am. J. Cardiovasc. Drugs 2007; 7: 39-58.